Summary
A well characterised and fully validated bioanalytical method used for measuring a novel porphyrin photodynamic therapy (CompoundI) in human plasma was modified in order to enable the measurement of a structurally and metabolically related compound (CompoundII) in rat plasma.
The modified method was validated, but after initial attempts to implement the method to support routine sample analysis failed, it was suspected that CompoundII was unstable in rat plasma.
The preparation of plasma Quality Control (QC) samples used during validation to evaluate precision, inaccuracy, stability and the on-going performance of the method, was closely scrutinised because of the limited solubility of this class of compound in aqueous solution. After investigating the solvent composition of standard solutions of CompoundII used during the preparation of QCs, together with the subsequent mixing techniques used to distribute the analyte in plasma, the limited solubility of CompoundII was eventually shown to be the cause of the “stability” problem.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Milgrom, L.; MacRobert, S.Chemistry in Britain, May1998.
Sharman, W.M.; Allen, C.M.; van Lier, J.E.DDT Vol. 4, No. 11, November1999.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, G.T., Yang, T., Baldock, G.A. et al. The impact of stability and solubility of photodynamic therapies on method development. Chromatographia 55 (Suppl 1), S171–S175 (2002). https://doi.org/10.1007/BF02493375
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02493375